Breadcrumb
RI-MUHC ANNUAL REPORT 2021YEAR IN REVIEWCARDIOVASCULAR HEALTH ACROSS THE LIFESPAN (CHAL) PROGRAMRESEARCH HIGHLIGHTSPersonalizing...
RI-MUHC ANNUAL REPORT 2021EXECUTIVE MESSAGESMESSAGE FROM MIGUEL BURNIER JR.During this extraordinary year, the COVID-19 pandemic forced the...
RI-MUHC ANNUAL REPORT 2021FUNDING SUMMARY AND WORLDWIDE NETWORKWe are proud of our researchers’ success in funding competitions and...
RI-MUHC ANNUAL REPORT 2021YEAR IN REVIEWTRANSLATIONAL RESEARCH IN RESPIRATORY DISEASES (RESP) PROGRAMRESEARCH HIGHLIGHTSHarnessing the...
RI-MUHC ANNUAL REPORT 2021THE RI-MUHC IN NUMBERS: 2020-2021 472 active members,including fundamental,clinical and evaluativeresearchers...
RI-MUHC ANNUAL REPORT 2021BUSINESS DEVELOPMENT ACTIVITIESREPURPOSING AN EXISTING DRUG TO TREAT COVID-19Dr. Elena Netchiporouk embarked on a...
RI-MUHC ANNUAL REPORT 2021YEAR IN REVIEWINFECTIOUS DISEASES AND IMMUNITY IN GLOBAL HEALTH (IDIGH) PROGRAMRESEARCH HIGHLIGHTSFirst...
Fundamentally changing how cardiologists approach older patients
RI-MUHC ANNUAL REPORT 2021YEAR IN REVIEWMETABOLIC DISORDERS AND COMPLICATIONS (MeDiC) PROGRAMRESEARCH HIGHLIGHTSUnderstanding the health...
RI-MUHC Annual Report
RI-MUHC Annual Report
Cellular Therapy Laboratory (CTL)The Cellular Therapy Laboratory (CTL) at the RI-MUHC was created to enhance research capabilities using...
Platform News
Research Life
What's New at the RI-MUHC ?
Congratulations to Tho-Alfakar Al-Aubodah!
RI-MUHC scientist Dr. Cecilia Costiniuk is co-principal investigator in a new national study that hopes to answer critical questions around the...
Mobile application EczemaQ wins the Hakim Family Innovation Prize. Remote Optical and Nura Medical were...
Canadian Bioethics Society honours a researcher who promotes the human right of every citizen to benefit from science and its applications
Specialized cells called pericytes play a key role, reveals new work from researchers at the RI-MUHC
Next-generation gene sequencing may provide answers for some women dealing with recurrent pregnancy loss and prevent further miscarriages
A team of researchers at the RI-MUHC found two cellular pathways involved in TNBC tumour development...
New target for cystic fibrosis drug development: Ceramides
Bringing an innovative retinal gene therapy to clinic
Speakers: Dr. Jason M. Harley (Principal Investigator, Department of Surgery) and Dr. Elif Bilgic (Postdoctoral Fellow)